Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $8.50B |
| Revenue Growth (YOY): 23.18% |
| Profit (% of Rev): 61.07% |
| Income (% of Rev): 33.28% |
| Income Growth (YOY): 63.58% |
| Operating Income: $2.05B |
| Operating Cash Flow: $3.57B |
| Operating Cash Flow Growth (YoY): 29.38% |
| Annual Dividend Yield: 0.70% |
| Total Assets: $90.88B |
| Total Liabilities: $83.36B |
| Cash & Equivalent: $9.01B |
| Total Debt: $60.40B |
| Debt/Equity: 8.02 |
| Quick Ratio: 0.96 |
| Current Ratio: 1.32 |
| Price/Book: 22.99 |
| Price/Earnings: 15.29 |
| EBITDA: $5.29B |
| EPS: 5.27 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.